Ad Header



The Pulse of the Pharmaceutical Industry

EU approves AstraZeneca lung cancer immunotherapy

Written by: | | Dated: Monday, September 24th, 2018


EU approves AstraZeneca immunotherapy drug for lung cancer


LONDON (Reuters) – AstraZeneca’s immunotherapy drug Imfinzi has been approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body, the drugmaker said on Monday.

The green light from the European Commission had been expected following a positive recommendation from experts at the European Medicines Agency in July.

The European approval is for patients whose tumors express a biomarker known as PD-L1 on 1 percent or more of tumor cells and whose disease has not progressed following platinum-based chemotherapy and radiation therapy.


Reporting by Ben Hirschler; Editing by Adrian Croft


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom